VBL Therapeutics Selected for €17.5 Million of Funding from Horizon Europe EIC Accelerator Program
20. Dezember 2021 07:30 ET
|
VBL Therapeutics
VBL is among only 9% of companies across industries selected by the EIC Accelerator Funds to be used for clinical development, CMC, and pre-commercialization activities for ofra-vec (VB-111) TEL...
VBL Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
15. November 2021 07:30 ET
|
VBL Therapeutics
Conference Call and Webcast at 8:30 a.m. ET Today Data from multiple VB-111 clinical trials expected in 2022, including the progression free survival (PFS) co-primary endpoint from the Phase 3 OVAL...
VBL Therapeutics to Report Third Quarter Financial Results on November 15
08. November 2021 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant...
VBL Therapeutics Announces Appointment of Sam Backenroth as Chief Financial Officer and Establishes Operations in the United States
05. Oktober 2021 08:00 ET
|
VBL Therapeutics
TEL AVIV, Israel and NEW YORK, Oct. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the appointment of Sam Backenroth as chief financial officer (CFO) effective...
VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer
17. September 2021 07:00 ET
|
VBL Therapeutics
The OVAL Phase 3 clinical trial evaluating VB-111 in platinum-resistant ovarian cancer has recruited more than 320 patients (>80 %) to date;Remains on track to complete enrollment in 1Q22 TEL...
VBL Therapeutics to Present at Upcoming Conferences
10. September 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: H.C. Wainwright 23rd...
VBL Therapeutics Resumes U.S. Enrollment in OVAL Phase 3 Trial as FDA Authorizes Clinical Use of VB-111 Batches Produced in Modiin Facility
30. August 2021 07:00 ET
|
VBL Therapeutics
U.S. FDA CMC clearance of VB-111 produced in Modiin, Israel facility an important milestone toward potential commercializationOVAL Phase 3 trial evaluating VB-111 in platinum resistant ovarian cancer...
VBL Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update
16. August 2021 07:00 ET
|
VBL Therapeutics
Conference Call and Webcast at 8:30 a.m. EDT Today ● Closed public offering raising net proceeds of $26.4 million; cash position is expected to fund operations until year-end 2023, through readout...
VBL Therapeutics to Report Second Quarter Financial Results on August 16
05. August 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, Aug. 05, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) will release its second quarter financial results for the period ended June 30, 2021 on Monday, August 16 before...
VBL Therapeutics Appoints Marc Kozin as Chairman of its Board of Directors
22. Juli 2021 07:00 ET
|
VBL Therapeutics
TEL AVIV, Israel, July 22, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced the planned elevation of Marc Kozin as chairman of the company’s board of directors. Bennett...